OVERVIEW
In September 2020, R-Zero engaged an independent clinical testing lab, to validate the efficacy of its flagship UV-C disinfection system, Arc, against human coronavirus, feline calicivirus (FCV), MRSA and E. coli carriers. R-Zero selected microorganisms endemic to the environments Arc will be used in, ensuring partners understand Arc’s efficacy against the harmful microorganism most important to them. The following represents the results of that testing.
Bioscience Laboratories, Inc is an EPA and FDA GLP-Compliant, ISO 17025 Accredited Testing Laboratory (American Association for Laboratory Accreditation, certificate number 3945.01). Tests were conducted at the Bioscience laboratory, 1755 South 19th Avenue, Bozeman, MT 59718.
TEST METHOD
Testing was designed to simulate consumer use and was based upon the procedures outlined in the American Society of Test Materials (ASTM) test methods designated:
- ASTM E1053-20, Standard Test Practice to Assess Virucidal Activity of Chemicals Intended for Disinfection of Inanimate, Nonporous Environmental Surface.
ASTM E3135-18, Standard Practice for Determining Antimicrobial Efficacy of Ultraviolet Germicidal Irradiation Against Microorganisms on Carriers with Simulated Soil
STUDY CONCLUSIONS
Under the conditions of this evaluation, R-Zero Arc reduced the infectivity of Human Coronavirus, strain 229E (ATCC #VR-740) and Feline Calicivirus, strain F9 (FCV; ATCC #VR-782) by an average of 99.99% following a 7 minutes exposure at a distance of 8 feet.
Arc also reduced the microbial populations of Escherichia coli (ATCC #25922) and Staphylococcus aureus MRSA (ATCC #33591) by an average of 99.99% following a 7 minutes exposure at a distance of 8 feet.
